The Week in Review #38
Good News and Setbacks During the Departed Week from the Prohost Portfolio
FIRMS WITH GOOD NEWS
The most important happening, with the most exciting positive impact, has come this time from our picked gene therapy company, Spark Therapeutics (ONCE). It was electrifying news, which announced acquisition by Roche (RHHBY) of Spark Therapeutics; at a price of $114.50 per share, adding $61 to Spark’s stock price, at the time of the acquisition. Prohost has put a 2019 target for this stock at $100 . . .
This content is for paid subscribers.
Prohost Letters March 5, 2019